The **Maharashtra Food and Drug Administration (FDA)** has taken decisive regulatory action against **Cadila Pharmaceuticals**, ordering an immediate market recall of its popular antacid medication, **Aciloc**. The recall, which encompasses a stock inventory valued at approximately Rs 2.45 crore, follows an investigation into what officials have labeled “deceptive” branding practices concerning the product’s packaging and labeling.
Regulatory authorities initiated the enforcement action after identifying discrepancies between the approved drug formulation and the promotional branding displayed on the product packaging. According to state officials, the labeling was found to be misleading to consumers and healthcare providers, potentially violating compliance standards set under the **Drugs and Cosmetics Act, 1940**.
**Aciloc**, a widely used brand containing **Ranitidine**, is a **histamine H2-receptor antagonist** primarily prescribed to reduce stomach acid production in patients suffering from **gastroesophageal reflux disease (GERD)**, **peptic ulcers**, and related digestive conditions. Because the drug is a staple in many households, the state FDA has prioritized the removal of the specific misbranded batches from distribution networks to prevent further public consumption.
The regulatory body has issued a formal directive to all wholesale and retail pharmacies across the region to halt the sale of the affected inventory immediately. Furthermore, **Cadila Pharmaceuticals** has been tasked with tracking the distribution chain to ensure that all implicated batches are withdrawn from the market.
Industry experts suggest that this move underscores a tightening of oversight by Indian drug regulators, who are increasingly focusing on the transparency of pharmaceutical labeling. Compliance with mandated design and information standards is essential to maintain patient safety, as any confusion regarding dosage or ingredients can lead to significant health risks for those managing chronic conditions.
While the current recall is localized to the specific branding irregularities identified by the **Maharashtra FDA**, the company is expected to undergo further scrutiny to ensure that their remaining portfolio aligns with current **Good Manufacturing Practices (GMP)** and labeling regulations. Patients currently relying on **Aciloc** for acid-related symptoms are advised to consult their pharmacists or medical practitioners regarding the safety of their current supply and to seek suitable alternatives if their specific batches are part of the recall list.
As of now, the company is cooperating with the regulatory authorities to facilitate the recall process, though the implications for their broader product distribution strategy remain under observation.
